XGN
Exagen Inc
Price:  
6.25 
USD
Volume:  
275,188.00
United States | Health Care Providers & Services
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

XGN WACC - Weighted Average Cost of Capital

The WACC of Exagen Inc (XGN) is 7.2%.

The Cost of Equity of Exagen Inc (XGN) is 7.25%.
The Cost of Debt of Exagen Inc (XGN) is 6.90%.

Range Selected
Cost of equity 5.40% - 9.10% 7.25%
Tax rate 0.30% - 0.50% 0.40%
Cost of debt 6.80% - 7.00% 6.90%
WACC 5.7% - 8.7% 7.2%
WACC

XGN WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.34 0.75
Additional risk adjustments 0.0% 0.5%
Cost of equity 5.40% 9.10%
Tax rate 0.30% 0.50%
Debt/Equity ratio 0.19 0.19
Cost of debt 6.80% 7.00%
After-tax WACC 5.7% 8.7%
Selected WACC 7.2%

XGN's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for XGN:

cost_of_equity (7.25%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.34) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.